April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Analysis of LOXL1 Expression in Lens Capsule Tissue Specimens From Individuals With Pseudoexfoliation and Primary Open-Angle Glaucoma
Author Affiliations & Notes
  • T. Khan
    Duke University School of Medicine, Durham, North Carolina
  • I. D. Navarro
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • R. Kastury
    LECOM-Bradenton, Bradenton, Florida
  • P. Gonzalez
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • P. Challa
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Footnotes
    Commercial Relationships  T. Khan, None; I.D. Navarro, None; R. Kastury, None; P. Gonzalez, None; P. Challa, None.
  • Footnotes
    Support  NIH K23 EY014019, core grant EY01894, EY016228, EY05722, Research to Prevent Blindness (RPB) Sybil B. Harrington Scholar Award
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2166. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Khan, I. D. Navarro, R. Kastury, P. Gonzalez, P. Challa; Analysis of LOXL1 Expression in Lens Capsule Tissue Specimens From Individuals With Pseudoexfoliation and Primary Open-Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2166.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate LOXL1 expression levels in freshly collected lens capsules from pseudoexfoliation syndrome (PEX), pseudoexfoliation glaucoma (PEXG), primary open angle glaucoma (POAG), and cataract control individuals. To study the effects of four glaucoma drugs on LOXL1 expression in immortalized and primary human lens epithelial cell cultures. The lens is a major site of PEX production and deposition.

Methods: : IRB approval was obtained prior to starting the study and informed consent was obtained from all participating individuals. Lens capsules were collected at the time of cataract surgery. Controls were matched to age, sex, and ethnicity. Total RNA was isolated from individual lens capsule samples and reverse transcript PCR was performed on each sample. Real-time PCR was performed using the beta-actin gene as a control. Cell cultures were grown to confluence and then treated with one of four glaucoma drugs once daily with simultaneous change of medium. Controls were not treated with any drug and media changed in the same manner. After one week of treatment, cells were harvested and total RNA isolated. Reverse transcript PCR was performed on each group of cells using LOXL1 and beta-actin primers.

Results: : 32 samples were analyzed (7 PEX, 7 PEXG, 8 POAG, and 10 control). LOXL1 expression was detected in the lens capsule specimens from all four groups. Gene expression was measured and normalized to control tissue expression. The results demonstrated significant differences between the control and PEXG; control and POAG; PEX and PEXG; and PEX and POAG. No significant difference was observed between the control and PEX or between PEXG and POAG. Real-time semi-quantitative PCR revealed no significant difference in LOXL1 gene expression between the un-treated control groups and the 1:1000 drug:media groups. At ten-fold higher concentrations (1:100 drug:media), brinzolamide, timolol maleate, and latanoprost showed a mild increase in LOXL1 expression relative to the control. This effect was not observed with brimonidine tartrate.

Conclusions: : These results establish that LOXL1 expression is markedly reduced in lens capsule specimens from both PEXG and POAG individuals. Decreases in LOXL1 expression observed in PEXG and POAG are not attributable to a drug-related etiology. Although LOXL1 polymorphisms are not associated with POAG, this data suggests that LOXL1 may play a yet uncharacterized role in the two disorders.

Keywords: gene/expression • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.